Evaluation of the immunotoxicity and allergenicity of a new intranasal influenza vector vaccine against tuberculosis carrying TB10.4 and HspX antigens

Document Type : Original Article


Smorodintsev Research Institute of Influenza, 197376, Ulitsa Professora Popova 15/17, St. Petersburg, Russian Federation



Objective(s): A new vaccine candidate TB/FLU-05E has been developed at the Smorodintsev Research Institute of Influenza (Russia). The vaccine is based on the attenuated influenza strain A/PR8/NS124-TB10.4-2A-HspX that expresses mycobacterial antigens TB10.4 and HspX. This article describes the results of preclinical immunotoxicity and allergenicity studies of the new vector vaccine TB/FLU-05E against tuberculosis. 
Materials and Methods: The experiments were conducted on male CBA mice, С57/black/6 mice, and guinea pigs. The vaccine candidate was administered intranasally (7.7 lg TCID50/animal and 8.0 lg TCID50/animal) twice at a 21-day interval. The immunotoxic properties of the vaccine were assessed in mice according to the following parameters: spleen and thymus weight and their organ-to-body weight ratio, splenic and thymic cellularity, hemagglutination titer assay, delayed-type hypersensitivity test, and phagocytic activity of peritoneal macrophages. Histological examination of the thymus and spleen and white blood cell counts were also performed. Allergenicity of the vaccine was assessed in guinea pigs using conjunctival and general anaphylaxis reaction tests.
Results: The results showed that double immunization with the TB/FLU-05E vaccine did not affect the phagocytic activity of peritoneal macrophages, cellular and humoral immunity after immunization with a heterologous antigen (sheep red blood cells), or the organ-to-body weight ratio of immunocompetent organs (thymus and spleen). The vaccine candidate demonstrated no allergenic properties.
Conclusion: According to the results of this study, the TB/FLU-05E vaccine is well-tolerated by the immune system and demonstrates no immunotoxicity or allergenicity.


1. WHO. Global tuberculosis report 2020. Geneva: World Health Organization; 2020.
2. Sable SB, Posey JE, Scriba TJ. Tuberculosis vaccine development: progress in clinical evaluation. Clin Microbiol Rev 2019; 33: e00100-19. 
3. Stewart E, Triccas JA, Petrovsky N. Adjuvant strategies for more effective tuberculosis vaccine immunity. Microorganisms 2019; 7: 255. 
4. Franco AR, Peri F. Developing new anti-tuberculosis vaccines: focus on adjuvants. Cells 2021; 10: 78. 
5. Vetter V, Denizer G, Friedland LR, Krishnan J, Shapiro M. Understanding modern-day vaccines: what you need to know. Ann Med 2018; 50: 110–120. 
6. Batista-Duharte A, Martínez DT, Carlos IZ. Efficacy and safety of immunological adjuvants. Where is the cut-off? Biomed Pharmacother 2018; 105: 616–624. 
7. Sampath V, Rabinowitz G, Shah M, Jain S, Diamant Z, Jesenak M, et al. Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives. Allergy 2021; 76: 1640–1660.
8. WHO. Guidelines on Nonclinical Evaluation of Vaccines. World Health Organization Technical Report Series 2005; 927: 31-63.
9. EMA. ICH guideline S6 (R1) – preclinical safety evaluation of biotechnology-derived pharmaceuticals (EMA/CHMP/ICH/731268/1998). European Medicines Agency; 2011.
10. EMA. Guideline on quality, non-clinical and clinical aspects of live recombinant viral vectored vaccines (EMA/CHMP/VWP/141697/2009),  European Medicines Agency; 2010.
11. Sergeeva MV, Romanovskaya-Romanko EA, Zabolotnyh NV, Pulkina AA, Vasilyev KA, Shurigina A-PS, et al. Mucosal influenza vector vaccine carrying TB10.4 and HspX antigens provides protection against mycobacterium tuberculosis in mice and guinea pigs. Vaccines (Basel) 2021; 9: 394.
12. Mironov AN, Bunatyan ND. Guideline for conducting pre-clinical study of medicinal products. Part 2. Moscow, Grif I K Publishers; 2012. 
13. Friemel H. Immunologische arbeitsmethoden (translated in Russian). Moscow: Mir; 1979.
14. Chae BS, Ahn, YK, Kim JH. Effect of Swainsonine on the humor immune response of lipopolysaccharide. Arch Pharm Res 1997; 20: 545-549.
15. Coles JA, Farley SR, Pipe RK. Alteration of the immune response of the common marine mussel Mytilus edulis resulting from exposure to cadmium. Dis Aquat Organ 1995; 22: 59-65.
16. EMA. ICH Topic S 8 Immunotoxicity Studies for Human Pharmaceuticals (CHMP/167235/2004). European Medicines Agency; 2005 
17. Vasilyev KA, Shurygina A-PS, Zabolotnykh NV, Sergeeva MV, Romanovskaya-Romanko EA, Pulkina AA, et al. Enhancement of the local CD8+ T-Cellular immune response to Mycobacterium Tuberculosis in BCG-primed mice after intranasal administration of influenza vector vaccine carrying TB10.4 and HspX Antigens. Vaccines (Basel) 2021; 9, 1273. 
18. World Health Organization. Meeting of the strategic advisory group of experts on immunization, April 2014 –- conclusions and recommendations. Wkly Epidemiol Rec 2014; 89: 221-36.
19. Messina NL, Zimmermann P, Curtis N. The impact of vaccines on heterologous adaptive immunity. Clin Microbiol Infect 2019; 25: 1484-1493.
20. Libraty DH, Zhang L, Woda M, et al. Neonatal BCG vaccination is associated with enhanced T-helper 1 immune responses to heterologous infant vaccines. Trials Vaccinol 2014; 3: 1-5.
21. Ritz N, Mui M, Balloch A, Curtis N. Non-specific effect of Bacille Calmette-Guerin vaccine on the immune response to routine immunisations. Vaccine 2013; 31: 3098-3103.
22. Ota MO, Vekemans J, Schlegel-Haueter SE, Fielding K, Sanneh M, Kidd M et al. Influence of Mycobacterium bovis bacillus Calmette-Guerin on antibody and cytokine responses to human neonatal vaccination. J Immunol 2002; 168: 919-925
23. Leentjens J, Kox M, Stokman R, Gerretsen J, Diavatopoulos DA, van Crevel R, et al. BCG vaccination enhances the immunogenicity of subsequent influenza vaccination in healthy volunteers: a randomized, placebo-controlled pilot study. J Infect Dis 2015; 212: 1930-1938.
24. Nissen TN, Birk NM, Smits G, Jeppesen DL, Stensballe LG, Netea MG, et al. Bacille Calmette-Guérin (BCG) vaccination at birth and antibody responses to childhood vaccines. A randomised clinical trial. Vaccine 2017; 35: 2084-2091.
25. Ritz N, Mui M, Balloch A, Curtis N. Non-specific effect of Bacille Calmette-Guerin vaccine on the immune response to routine immunisations. Vaccine 2013; 31: 3098–3103.
26. Blok BA, Arts RJW, van Crevel R, Aaby P, Joosten LAB, Benn CS, et al. Differential effects of BCG vaccine on immune responses induced by vi polysaccharide typhoid fever vaccination: an explorative randomized trial. Eur J Clin Microbiol Infect Dis 2020; 39: 1177-1184.
27.  Tarancón R, Domínguez-Andrés J, Uranga S, Ferreira AV, Groh LA, Domenech M, et al. New live attenuated tuberculosis vaccine MTBVAC induces trained immunity and confers protection against experimental lethal pneumonia. PLoS Pathog 2020; 16: e1008404.
28. Irving CA (ed.). Mouse Models of Innate Immunity: Methods and Protocols (Methods in Molecular Biology, 1031). Humana; 2013.
29. Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Ifrim DC, Saeed S, et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci U S A 2012; 109: 17537–17542.
30. Jensen KJ, Larsen N, Biering-Sorensen SB, Andersen A, Eriksen HB, Monteiro I, et al. Heterologous immunological effects of early BCG vaccination in low-birth-weight infants in Guinea-Bissau: A randomized-controlled trial. J Infect Dis 2015; 211: 956-967. 
31. Kleinnijenhuis J, Quintin J, Preijers F, Benn CS, Joosten LA, Jacobs C, et al. Long-lasting effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunity. J Innate Immun. 2014; 6: 152-158.
32. Raza M, Al-Shabanah OA, El-Hadiyah TM, Al-Majed AA. Effect of prolonged vigabatrin treatment on haematological and biochemical parameters in plasma, liver and kidney of Swiss albino mice. Sci Pharm 2002; 70: 135–145.
33. Peleteiro TS, Oliveira ES, Conceição EL, Nascimento-Sampaio F, Alcântara-Neves NM, Mendes CMC, et al. Impact of Bacille Calmette-Guérin revaccination on serum IgE levels in a randomized controlled trial. Rev Soc Bras Med Trop 2018; 51: 94-98.
34. Buzitskaya ZV, Stosman KI, Khairullin BM, Kassenov MM, Nurpeisova AS , Sansyzbay AA, et al. New intranasal influenza vector-based vaccine TB/FLU-04L against tuberculosis: Preclinical Safety Studies. Drug Res (Stuttg) 2022; 72: 255-258.
35. Stosman KI, Sivak KV, Aleksandrov AG, Buzitskaya ZV, Rassokha TA, Stukova MA. Preclinical safety evaluation: Acute and repeated-dose toxicity of a new intranasal vaccine against tuberculosis. Drug Res (Stuttg) 2022; 72: 215-219.